2023 Was a tough year to the biopharma market, with a number of corporations downsizing and restructuring their workforces to stay afloat. There are actually indications of Restoration, as mergers and acquisitions picked up over the pharmaceutical and everyday living sciences business while in the latter part of 2023 and https://sites.google.com/view/bio-sites/blog